Form D · Biotechnology

ProPhase Labs, Inc.

Uniondale, NY · CIK 0000868278

Offering snapshot reported Aug 5, 2025 · SEC filing

Reported sold
$3M
Offering amount: $6M
Investors reported
2
Form D · investor count
Minimum accepted
$500K
Reported outside-investor minimum
First sale
Jul 22, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 5, 2025Initial$3,000,000No comparison2SEC filing
Jul 7, 2025Initial$1,000,000No comparison2SEC filing
Dec 28, 2015Initial$1,500,000No comparison2SEC filing
Mar 26, 2010Initial$2,923,200No comparison1SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-553763

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
NoneNone

Source: Form D, filed Aug 5, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Carolina Abenante Director
Jason Barr Director
Mark Burnett Director
Robert V. Cuddihy, Jr. Executive
John De Shazo Director
Mark Frank Director
Louis Geckel Director
Louis Gleckel Director
Warren Hirsch Director
Ted Karkus Director, Executive
Mark Leventhal Director
James Mc Cubbin Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
626 Rxr Plaza, 6 Th Floor
Uniondale, NY, 11556